Tags

Type your tag names separated by a space and hit enter

Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy.
Horm Metab Res. 2012 Jun; 44(6):482-7.HM

Abstract

Interleukine-16 (IL-16) and RANTES (regulated upon activation, normal T cell expressed and secreted) are 2 cytokines with the function of T helper cell recruitment, which might play a key role in pathogenesis of autoimmune thyroid diseases (AITD). This study was aimed to evaluate the IL-16 and RANTES in patients with AITD. Serum IL-16 and RANTES levels were measured in patients with Graves' disease (GD; n=45), Hashimoto's thyroiditis (HT; n=68), nontoxic multinodular goiter (NTMNG; n=20), and healthy individuals (n=61). The results showed that serum IL-16 and RANTES levels were elevated both in HT and higher in untreated GD patients when compared to NTMNG patients and the healthy individuals, which were decreased after MMI therapy in untreated GD patients. However, in HT patients, serum IL-16 and RANTES levels were comparable among the conditions of hyperthyroid and euthyroid received by l-thyroxine therapy and untreated hypothyroid. Furthermore, serum IL-16 levels were correlated with FT3, FT4, TRAb in GD, but not in HT patients. The data did not show any correlation between RANTES levels and clinical factors. In conclusion, IL-16 and RANTES might be involved in the pathogenesis of GD and HT, and serum IL-16 levels in GD maybe a potential marker of disease activity and severity.

Authors+Show Affiliations

Department of Endocrine and Metabolic Diseases, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou City, Zhejiang Province, P. R. China.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

22473756

Citation

Gu, X, et al. "Elevated Serum IL-16 and RANTES Levels in Patients With Autoimmune Thyroid Diseases and Modulation By Methimazole Therapy." Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, vol. 44, no. 6, 2012, pp. 482-7.
Gu X, Zheng L, Chen X, et al. Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy. Horm Metab Res. 2012;44(6):482-7.
Gu, X., Zheng, L., Chen, X., Ruan, L., Zhang, H., Ge, S., Zhu, H., Lin, X., & Shen, F. (2012). Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy. Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Metabolisme, 44(6), 482-7. https://doi.org/10.1055/s-0032-1308973
Gu X, et al. Elevated Serum IL-16 and RANTES Levels in Patients With Autoimmune Thyroid Diseases and Modulation By Methimazole Therapy. Horm Metab Res. 2012;44(6):482-7. PubMed PMID: 22473756.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated serum IL-16 and RANTES levels in patients with autoimmune thyroid diseases and modulation by methimazole therapy. AU - Gu,X, AU - Zheng,L, AU - Chen,X, AU - Ruan,L, AU - Zhang,H, AU - Ge,S, AU - Zhu,H, AU - Lin,X, AU - Shen,F, Y1 - 2012/04/02/ PY - 2012/4/5/entrez PY - 2012/4/5/pubmed PY - 2012/12/12/medline SP - 482 EP - 7 JF - Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme JO - Horm. Metab. Res. VL - 44 IS - 6 N2 - Interleukine-16 (IL-16) and RANTES (regulated upon activation, normal T cell expressed and secreted) are 2 cytokines with the function of T helper cell recruitment, which might play a key role in pathogenesis of autoimmune thyroid diseases (AITD). This study was aimed to evaluate the IL-16 and RANTES in patients with AITD. Serum IL-16 and RANTES levels were measured in patients with Graves' disease (GD; n=45), Hashimoto's thyroiditis (HT; n=68), nontoxic multinodular goiter (NTMNG; n=20), and healthy individuals (n=61). The results showed that serum IL-16 and RANTES levels were elevated both in HT and higher in untreated GD patients when compared to NTMNG patients and the healthy individuals, which were decreased after MMI therapy in untreated GD patients. However, in HT patients, serum IL-16 and RANTES levels were comparable among the conditions of hyperthyroid and euthyroid received by l-thyroxine therapy and untreated hypothyroid. Furthermore, serum IL-16 levels were correlated with FT3, FT4, TRAb in GD, but not in HT patients. The data did not show any correlation between RANTES levels and clinical factors. In conclusion, IL-16 and RANTES might be involved in the pathogenesis of GD and HT, and serum IL-16 levels in GD maybe a potential marker of disease activity and severity. SN - 1439-4286 UR - https://www.unboundmedicine.com/medline/citation/22473756/Elevated_serum_IL_16_and_RANTES_levels_in_patients_with_autoimmune_thyroid_diseases_and_modulation_by_methimazole_therapy_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-0032-1308973 DB - PRIME DP - Unbound Medicine ER -